Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

128.12 -1.26 (-0.98%)
Streaming Delayed Price Updated: 1:04 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
44 45 Next >
Top Analyst Reports For T-Mobile US, Abbott Laboratories & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW). 
Via Talk Markets
Analyst Ratings For Abbott Laboratories
Via Benzinga
FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries
FDA approves Abbott Laboratories' TriClip TEER system for treating tricuspid regurgitation. Clip technology offers non-invasive repair, fast recovery, and significant improvement in quality of life.... 
Via Benzinga
Exposures Product Safety
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Russell 2000 Index Best And Worst Performing Stocks Of 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Abbott Laboratories?
Via Benzinga
Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment &amp; Supplies Industry
Via Benzinga
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
In an aging world, strong buy healthcare stocks like UNH, ABT, and MRK shine with dividends, innovation, and market growth. 
Via InvestorPlace
Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval
Discover the investment potential of three stocks with analyst approval for their robust financials and strategic market positions. 
Via InvestorPlace
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
Investors should take notice of these stocks with high analyst ratings. It's time to load up your portfolio. 
Via InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now.
There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing. 
Via The Motley Fool
3 Stocks to Buy Right Now for the Coming Recession
With numerous economic indicators souring, these three stocks to buy for a recession will protect your portfolio's downside. 
Via InvestorPlace
Topics Economy
Exposures Economy
What the Options Market Tells Us About Abbott Laboratories
Via Benzinga
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy? 
Via The Motley Fool
3 Resilient Stocks to Protect Your Wealth During a Recession
Discover three recession-resistant stocks with growth leads in the consumer staples, household products, and healthcare industries. 
Via InvestorPlace
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Exposures Death
What's Going On With Abbott Laboratories Stock On Friday?
An Illinois jury orders Reckitt Benckiser's Mead Johnson to pay $60 million after a premature infant's tragic death linked to Enfamil baby formula. Mead Johnson found negligent for not warning about... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
Exposures Death
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors. 
Via InvestorPlace
Topics ETFs
Exploring ABBOTT LABORATORIES (NYSE:ABT)s quality characteristics.
Why the quality investor may take a look at ABBOTT LABORATORIES (NYSE:ABT). 
Via Chartmill
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Medtronic is a Dividend Aristocrat That Keeps Gaining
A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector 
Via MarketBeat
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry. 
Via The Motley Fool
Are These 5 Undervalued Stocks Ready to Break Out?
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
Via MarketBeat
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant... 
Via Benzinga
Exposures Product Safety
3 Dividend Aristocrats With the Largest 10-Year Dividend Growth Rates
These three dividend stocks have proved themselves to be among the best Dividend Aristocrats to buy for high-growth returns. 
Via InvestorPlace
Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
Via Investor's Business Daily
Exposures Product Safety
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant. 
Via The Motley Fool
Nearing Retirement? These Stocks Are as Cautious as They Come
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.